-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On December 7, Hunan Dajia Weikang Pharmaceutical Industry Co.
, Ltd.
(hereinafter referred to as "Dajia Weikang") was officially listed on the GEM of the Shenzhen Stock Exchange
.
The company's issuance price is 12.
37 yuan, the issuance price-earnings ratio is 40.
58 times, a total of 51,626,425 new shares are issued, and the total fundraising amount is 639 million yuan, which is 129 million yuan higher than the planned fundraising.
The funds raised will be mainly used for the company's intelligent logistics center Construction, chain pharmacy expansion and repayment of bank loans
.
On the first day of listing, Dajia Weikang’s opening price was 26 yuan per share, a 110.
19% increase from the issue price
.
In addition, the new stock soared more than 120% during the session
.
The current total market value is 5.
070 billion
.
According to the data, Dajia Weikang is a regional pharmaceutical distribution enterprise, mainly engaged in the distribution and retail business of medicines, biological products, medical equipment and other products
.
The main business includes pharmaceutical distribution, pharmaceutical retail and reproductive hospitals, among which the pharmaceutical distribution business revenue accounts for more than 70% of the total revenue
.
In the first half of 2021, its pharmaceutical distribution revenue accounted for 73.
44% of its total revenue, followed by pharmaceutical retail, which accounted for 26.
22% of its revenue, and reproductive hospitals only accounted for 0.
34%
.
From the perspective of business layout, Hunan Province is the main force of Dajia Weikang
.
Financial data shows that in 2018, 2019, 2020 and the first half of 2021, the company's revenue from Hunan Province accounted for more than 96%
.
Dajia Weikang also said that the company's pharmaceutical chain retail business and pharmaceutical distribution business are currently mainly carried out in Hunan Province, with obvious regional characteristics and a large degree of dependence on the Hunan Province market.
In the future, the company may be squeezed by other enterprises in Hunan Province.
market share risk
.
To this end, Dajia Weikang has established subsidiaries and branches in Shandong and Hainan, but there are also operational risks in the development of cross-regional operations
.
In recent years, with the implementation and continuous advancement of policies such as the "two-invoice system", the cancellation of the proportion of drugs, and the "4+7" centralized procurement, the competition in the pharmaceutical distribution industry has become more intense, and major listed chain pharmacies are actively deploying DTP (directly facing the patient sales model) pharmacy
.
Dajia Weikang also actively promotes the layout of DTP pharmacies.
As of September 30, 2021, it has opened 37 DTP professional pharmacies, forming a DTP pharmacy layout with Changsha as the center and covering 14 cities and states in Hunan Province.
It operates 278 new and special medicines
.
However, what needs to be seen is that Dajia Weikang also faces many competitors in the field of DTP pharmacies, including Hunan Wei'an Pharmacy Chain Co.
, Ltd.
under Sinopharm Holding, and the probiotic drug number of Hunan Regal Pharmaceutical Co.
, Ltd.
under China Resources.
As well as Liuyao Co.
, Ltd.
, ordinary people, etc.
, compared with listed companies in the same industry, the single-store income level of Dajia Weikang DTP pharmacy is at a medium level
.
In order to seek new growth points for performance, Dajia Weikang is also deploying to hospital terminals in the field of reproductive hospitals, and opened Jiachen Hospital, a specialized hospital for reproductive health and infertility.
The hospital started trial operation in April 2019, but it is still in the process of supporting In the preparation and preparation stage of reproductive business, coupled with the large investment in the early stage, it is still in a state of loss
.
Financial data shows that in 2019, 2020 and the first half of 2021, the net profit of Jiachen Hospital was -5.
4798 million yuan, -6.
2219 million yuan, and -4.
3206 million yuan respectively
.
Based on the current development status, Dajia Weikang believes that the chain expansion of retail pharmacies will help it increase its regional market share, and the improvement of storage and transportation capacity will help the company to reduce costs and increase efficiency
.
Therefore, the funds raised this time are mainly used for chain pharmacy expansion projects, intelligent logistics center projects and repayment of bank loans
.
Among them, the planned intelligent logistics center plans to build two logistics warehouses in the existing factory area, namely the No.
2 and No.
3 warehouses of the intelligent logistics center, with a total new construction area of 21,804.
56m2, supporting intelligent storage systems, equipment and vehicles
.
The prospectus shows that after the completion of this project, it will help to improve the company's storage and transportation capacity, help the company to further expand its business scale, and provide a guarantee for sustainable and stable development
.
, Ltd.
(hereinafter referred to as "Dajia Weikang") was officially listed on the GEM of the Shenzhen Stock Exchange
.
The company's issuance price is 12.
37 yuan, the issuance price-earnings ratio is 40.
58 times, a total of 51,626,425 new shares are issued, and the total fundraising amount is 639 million yuan, which is 129 million yuan higher than the planned fundraising.
The funds raised will be mainly used for the company's intelligent logistics center Construction, chain pharmacy expansion and repayment of bank loans
.
On the first day of listing, Dajia Weikang’s opening price was 26 yuan per share, a 110.
19% increase from the issue price
.
In addition, the new stock soared more than 120% during the session
.
The current total market value is 5.
070 billion
.
According to the data, Dajia Weikang is a regional pharmaceutical distribution enterprise, mainly engaged in the distribution and retail business of medicines, biological products, medical equipment and other products
.
The main business includes pharmaceutical distribution, pharmaceutical retail and reproductive hospitals, among which the pharmaceutical distribution business revenue accounts for more than 70% of the total revenue
.
In the first half of 2021, its pharmaceutical distribution revenue accounted for 73.
44% of its total revenue, followed by pharmaceutical retail, which accounted for 26.
22% of its revenue, and reproductive hospitals only accounted for 0.
34%
.
From the perspective of business layout, Hunan Province is the main force of Dajia Weikang
.
Financial data shows that in 2018, 2019, 2020 and the first half of 2021, the company's revenue from Hunan Province accounted for more than 96%
.
Dajia Weikang also said that the company's pharmaceutical chain retail business and pharmaceutical distribution business are currently mainly carried out in Hunan Province, with obvious regional characteristics and a large degree of dependence on the Hunan Province market.
In the future, the company may be squeezed by other enterprises in Hunan Province.
market share risk
.
To this end, Dajia Weikang has established subsidiaries and branches in Shandong and Hainan, but there are also operational risks in the development of cross-regional operations
.
In recent years, with the implementation and continuous advancement of policies such as the "two-invoice system", the cancellation of the proportion of drugs, and the "4+7" centralized procurement, the competition in the pharmaceutical distribution industry has become more intense, and major listed chain pharmacies are actively deploying DTP (directly facing the patient sales model) pharmacy
.
Dajia Weikang also actively promotes the layout of DTP pharmacies.
As of September 30, 2021, it has opened 37 DTP professional pharmacies, forming a DTP pharmacy layout with Changsha as the center and covering 14 cities and states in Hunan Province.
It operates 278 new and special medicines
.
However, what needs to be seen is that Dajia Weikang also faces many competitors in the field of DTP pharmacies, including Hunan Wei'an Pharmacy Chain Co.
, Ltd.
under Sinopharm Holding, and the probiotic drug number of Hunan Regal Pharmaceutical Co.
, Ltd.
under China Resources.
As well as Liuyao Co.
, Ltd.
, ordinary people, etc.
, compared with listed companies in the same industry, the single-store income level of Dajia Weikang DTP pharmacy is at a medium level
.
In order to seek new growth points for performance, Dajia Weikang is also deploying to hospital terminals in the field of reproductive hospitals, and opened Jiachen Hospital, a specialized hospital for reproductive health and infertility.
The hospital started trial operation in April 2019, but it is still in the process of supporting In the preparation and preparation stage of reproductive business, coupled with the large investment in the early stage, it is still in a state of loss
.
Financial data shows that in 2019, 2020 and the first half of 2021, the net profit of Jiachen Hospital was -5.
4798 million yuan, -6.
2219 million yuan, and -4.
3206 million yuan respectively
.
Based on the current development status, Dajia Weikang believes that the chain expansion of retail pharmacies will help it increase its regional market share, and the improvement of storage and transportation capacity will help the company to reduce costs and increase efficiency
.
Therefore, the funds raised this time are mainly used for chain pharmacy expansion projects, intelligent logistics center projects and repayment of bank loans
.
Among them, the planned intelligent logistics center plans to build two logistics warehouses in the existing factory area, namely the No.
2 and No.
3 warehouses of the intelligent logistics center, with a total new construction area of 21,804.
56m2, supporting intelligent storage systems, equipment and vehicles
.
The prospectus shows that after the completion of this project, it will help to improve the company's storage and transportation capacity, help the company to further expand its business scale, and provide a guarantee for sustainable and stable development
.
